Different Cardiotoxicity of Palbociclib and Ribociclib in ... - PubMed
WEBOur results show that ribociclib, but not palbociclib, could act by down-regulating the expression of KCNH2 (encoding for potassium channel hERG) and up-regulating SCN5A and SNTA1 (encoding for sodium channels Nav1.5 and syntrophin-α1, respectively), three genes associated with long QT syndrome.
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast …
WEBSep 16, 2019 · Our results show that ribociclib, but not palbociclib, could act by down-regulating the expression of KCNH2 (encoding for potassium channel hERG) and up-regulating SCN5A and SNTA1 (encoding for sodium channels Nav1.5 and syntrophin-α1, respectively), three genes associated with long QT syndrome.
A Comprehensive Review of Clinical Cardiotoxicity Incidence …
WEBJun 12, 2020 · Ribociclib and abemaciclib is an SMKI that specifically inhibits CDK4/6, which overexpresses in hormone receptor (HR)-positive breast cancer. The FDA approved ribociclib and abemaciclib a first-line therapies for the treatment of postmenopausal women whose tumors are HR-positive, HER2-negative.
Ribociclib-Induced Cutaneous Adverse Events in Metastatic …
WEBJan 18, 2024 · Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematological, hepatic, and cardiac adverse events (AEs) emerged from pivotal trials, but little is known about cutaneous adverse events (CAEs).
Ribociclib plus Endocrine Therapy in Early Breast Cancer
WEBMar 20, 2024 · The absolute benefit with ribociclib plus an NSAI at 3 years was 3.3 percentage points. These results support the use of ribociclib in the treatment of HR-positive, HER2-negative early breast...
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone ...
WEBMay 31, 2023 · Background: RIB and PAL are CDK4/6 inhibitors with demonstrated efficacy in terms of progression-free survival (PFS) and similar tolerability in pts with HR+/HER2- ABC when combined with endocrine therapy (ET).
Ribociclib as First-Line Therapy for HR-Positive, Advanced …
WEBNov 3, 2016 · Ribociclib (LEE011) is an orally bioavailable, selective, small-molecule inhibitor of CDK4/6 that blocks the phosphorylation of retinoblastoma protein, thereby preventing cell-cycle progression...
Ribociclib Improves Overall Survival in HR+/HER2– Metastatic …
WEBMar 28, 2022 · Ribociclib significantly improved OS for patients with luminal A (HR, 0.75; p = .021), luminal B (HR, 0.69; p = .023), and HER2-enriched tumor subtypes (HR, 0.60; p = .018). In contrast, ribociclib did not improve OS relative to placebo in patients with basal-like tumors (HR, 1.89; p = .148).
WEBOct 8, 2016 · Ribociclib (LEE011) is an orally bioavailable, selective, small-molecule inhibitor of CDK4/6 that blocks the phosphorylation of retinoblastoma protein, thereby preventing cell-cycle progression
FDA Approves Ribociclib for Frontline HR+/HER2- Breast Cancer
WEBMar 13, 2017 · The FDA has approved the CDK 4/6 inhibitor ribociclib (Kisqali) for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with...
Skip to content